Pia Wegman1, Cecilia Ahlin, Bengt Sorbe. 1. Division of Clinical Medicine, School of Health and Medical Sciences, Örebro University, Örebro, Sweden. pia.wegman@oru.se
Abstract
INTRODUCTION: A high incidence of K-Ras mutations has been identified in a variety of human cancers, especially in codon 12, 13, and 61. Nevertheless, the presence of K-Ras mutations in cervical cancer remains controversial. The aim of this study was to investigate possible mutations in exon 1 and 2 of the K-Ras gene and to assess whether K-Ras mutation status had prognostic and predictive significance and were linked to clinicopathological parameters. METHODS: Genomic DNA from 107 patients with cervical cancer, treated with radiochemotherapy, were examined for mutations in the coding exons 1 and 2, including exon/intron borders of the K-Ras gene using single-stranded conformation polymorphism and sequence analyses. RESULTS: K-Ras mutations were detected in 11 patients (10%). Seven tumors showed a mutation in codon 59, 3 tumors in codon 38, and 1 tumor in codon 13. In 6 of the cases with a mutation in codon 59, an additional alteration located in codon 65 was found.Patients with K-Ras mutations had significantly worse recurrence-free survival (P = 0.03), and an association between K-Ras status and distant metastases was also seen (P = 0.04). CONCLUSIONS: The present data indicate that K-Ras mutations are relatively uncommon in cervical cancer but associates with poorer prognosis, especially in the subset of squamous cell carcinomas. There is a need for new markers in cervical cancer to improve individual treatment, but whether K-Ras mutation status is a potential biomarker in this situation needs further investigations in larger tumor series and in more regions of the K-Ras gene.
INTRODUCTION: A high incidence of K-Ras mutations has been identified in a variety of humancancers, especially in codon 12, 13, and 61. Nevertheless, the presence of K-Ras mutations in cervical cancer remains controversial. The aim of this study was to investigate possible mutations in exon 1 and 2 of the K-Ras gene and to assess whether K-Ras mutation status had prognostic and predictive significance and were linked to clinicopathological parameters. METHODS: Genomic DNA from 107 patients with cervical cancer, treated with radiochemotherapy, were examined for mutations in the coding exons 1 and 2, including exon/intron borders of the K-Ras gene using single-stranded conformation polymorphism and sequence analyses. RESULTS:K-Ras mutations were detected in 11 patients (10%). Seven tumors showed a mutation in codon 59, 3 tumors in codon 38, and 1 tumor in codon 13. In 6 of the cases with a mutation in codon 59, an additional alteration located in codon 65 was found.Patients with K-Ras mutations had significantly worse recurrence-free survival (P = 0.03), and an association between K-Ras status and distant metastases was also seen (P = 0.04). CONCLUSIONS: The present data indicate that K-Ras mutations are relatively uncommon in cervical cancer but associates with poorer prognosis, especially in the subset of squamous cell carcinomas. There is a need for new markers in cervical cancer to improve individual treatment, but whether K-Ras mutation status is a potential biomarker in this situation needs further investigations in larger tumor series and in more regions of the K-Ras gene.
Authors: Minjing Zou; Essa Y Baitei; Ali S Alzahrani; Faisal S BinHumaid; Dania Alkhafaji; Roua A Al-Rijjal; Brian F Meyer; Yufei Shi Journal: Thyroid Date: 2014-06-10 Impact factor: 6.568
Authors: Paula Böttinger; Karin Schreiber; Elizabeth Hyjek; Thomas Krausz; Michael T Spiotto; Madeline Steiner; Christian Idel; Heather Booras; Gabriele Beck-Engeser; Jessie Riederer; Gerald Willimsky; Steven P Wolf; Theodore Karrison; Elizabeth Jensen; Ralph R Weichselbaum; Yusuke Nakamura; Poh Yin Yew; Paul F Lambert; Takeshi Kurita; Kazuma Kiyotani; Matthias Leisegang; Hans Schreiber Journal: Carcinogenesis Date: 2020-11-13 Impact factor: 4.944
Authors: Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch Journal: Cancer Date: 2013-08-23 Impact factor: 6.860
Authors: Vivian M Spaans; Marjolijn D Trietsch; Stijn Crobach; Ellen Stelloo; Dennis Kremer; Elisabeth M Osse; Natalja T ter Haar; Ronald van Eijk; Susanne Muller; Tom van Wezel; J Baptist Trimbos; Tjalling Bosse; Vincent T H B M Smit; Gert Jan Fleuren Journal: PLoS One Date: 2014-03-26 Impact factor: 3.240
Authors: Mahmoud Toulany; Mari Iida; Simone Keinath; Firdevs F Iyi; Katharina Mueck; Birgit Fehrenbacher; Wael Y Mansour; Martin Schaller; Deric L Wheeler; H Peter Rodemann Journal: Oncotarget Date: 2016-07-12